OverviewSuggest Edit

Harrow Health (formerly Imprimis Pharmaceuticals) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. It also owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.

TypePublic
Founded2012
HQSan Diego, CA, US
Websiteharrowinc.com

Latest Updates

Employees (est.) (Mar 2020)133
Job Openings16
Revenue (FY, 2020)$48.9 M(-4%)
Share Price (Nov 2021)$11.1
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Harrow Health

Mark L. Baum

Mark L. Baum

Founder , Chief Executive Officer and Chairman of the board of directors
Andrew R. Boll

Andrew R. Boll

Chief Financial Officer
Teresa F. Sparks

Teresa F. Sparks

Member, Board of Directors, Independent Director
John P. Saharek

John P. Saharek

President, ImprimisRx
Dennis E. Saadeh

Dennis E. Saadeh

Chief of Formulation Strategy
Show more

Harrow Health Office Locations

Harrow Health has offices in San Diego, Cottonwood Heights, Irvine, Nashville and in 1 other location
San Diego, CA, US (HQ)
12264 El Camino Real #350
Cottonwood Heights, UT, US
2469 Fort Union Blvd STE 214
Irvine, CA, US
9257 Research Dr
Nashville, TN, US
102 Woodmont Blvd
Roxbury Township, NJ, US
1705 US-46 #6b, Ledgewood
Show all (5)

Harrow Health Financials and Metrics

Harrow Health Revenue

Harrow Health's revenue was reported to be $48.87 m in FY, 2020
USD

Revenue (Q1, 2021)

15.4m

Gross profit (Q1, 2021)

11.7m

Gross profit margin (Q1, 2021), %

75.6%

Net income (Q1, 2021)

217.0k

EBIT (Q1, 2021)

2.9m

Market capitalization (12-Nov-2021)

300.1m

Closing stock price (12-Nov-2021)

11.1

Cash (31-Mar-2021)

6.5m

EV

314.5m
Harrow Health's current market capitalization is $300.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

100.0k10.0k1.7m9.7m19.9m26.8m41.4m51.2m48.9m

Revenue growth, %

485%105%

Cost of goods sold

16.5m16.7m14.5m

Gross profit

24.9m34.4m34.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

100.0k2.5k2.5k2.5k1.4k667.7k441.0k1.6m2.0m2.7m4.4m4.9m4.9m6.1m6.9m6.5m8.9m10.4m10.7m12.3m13.5m12.8m11.8m8.1m15.4m

Cost of goods sold

4.2m4.2m3.9m5.2m4.1m3.6m3.2m3.8m

Gross profit

6.2m6.5m8.4m8.3m8.7m8.2m4.9m11.7m

Gross profit Margin, %

60%61%68%61%68%69%60%76%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

146.2k10.0m15.6m8.2m2.7m8.9m4.0m6.8m4.9m4.1m

Accounts Receivable

81.3k840.0k2.9m1.5m1.9m2.0m2.7m

Prepaid Expenses

14.8k61.6k105.1k240.4k786.0k714.0k837.0k1.3m751.0k

Inventories

372.7k1.4m1.8m2.2m1.8m3.3m4.0m
USDQ2, 2011

Financial Leverage

-0.1 x
Show all financial metrics

Harrow Health Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Harrow Health Online and Social Media Presence

Embed Graph

Harrow Health News and Updates

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the market clos…

Harrow Health Granted Two Patents for Novel Surgical Dilation Formulation

Data from Newly Patented Surgical Dilation Formulation to be Presented at the ASCRS 2021 Annual Meeting Data from Newly Patented Surgical Dilation Formulation to be Presented at the ASCRS 2021 Annual Meeting

Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026

NASHVILLE, Tenn., June 17, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amount of 8.625% senior…

Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones

NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that it has commenced an underwritten registered public offering of $17.5 million aggregate principal amount of its 8…

Harrow Health Launches New Corporate and Investor Website

NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its newly redesigned corporate and investor website, harrowinc.com. The new website, which is mobile-fr…

Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock

NASHVILLE, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that the Company has closed on a private sale to B. Riley Securities, Inc. of 440,000 shares of its newly created Seri…
Show more

Harrow Health Blogs

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

Harrow Health Announces Record First Quarter 2021 Financial Results

Harrow Health Announces Record First Quarter 2021 Financial Results

Harrow Health Announces Fourth Quarter and Year-End 2020 Financial Results

Harrow Health Announces Fourth Quarter and Year-End 2020 Financial Results

Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal

Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal

Harrow Health Publishes Third Quarter 2020 Letter to Stockholders

Harrow Health Publishes Third Quarter 2020 Letter to Stockholders

Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020

Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
Show more

Harrow Health Frequently Asked Questions

  • When was Harrow Health founded?

    Harrow Health was founded in 2012.

  • Who are Harrow Health key executives?

    Harrow Health's key executives are Mark L. Baum, Andrew R. Boll and Teresa F. Sparks.

  • How many employees does Harrow Health have?

    Harrow Health has 133 employees.

  • What is Harrow Health revenue?

    Latest Harrow Health annual revenue is $48.9 m.

  • What is Harrow Health revenue per employee?

    Latest Harrow Health revenue per employee is $367.5 k.

  • Who are Harrow Health competitors?

    Competitors of Harrow Health include Laboratorios VALMOR, Teva Pharmaceuticals and Porton Biopharma.

  • Where is Harrow Health headquarters?

    Harrow Health headquarters is located at 12264 El Camino Real #350, San Diego.

  • Where are Harrow Health offices?

    Harrow Health has offices in San Diego, Cottonwood Heights, Irvine, Nashville and in 1 other location.

  • How many offices does Harrow Health have?

    Harrow Health has 5 offices.